- Home
- DRTS vs TIL Comparison
DRTS vs TIL Comparison
Compare DRTS & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRTS
- TIL
- Stock Information
- Founded
- DRTS 2015
- TIL 2018
- Country
- DRTS Israel
- TIL United States
- Employees
- DRTS N/A
- TIL N/A
- Industry
- DRTS Medical/Dental Instruments
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- DRTS Health Care
- TIL Health Care
- Exchange
- DRTS Nasdaq
- TIL Nasdaq
- Market Cap
- DRTS 159.1M
- TIL 134.5M
- IPO Year
- DRTS N/A
- TIL 2021
- Fundamental
- Price
- DRTS $3.09
- TIL $21.39
- Analyst Decision
- DRTS Strong Buy
- TIL Buy
- Analyst Count
- DRTS 2
- TIL 4
- Target Price
- DRTS $8.00
- TIL $100.33
- AVG Volume (30 Days)
- DRTS 59.0K
- TIL 105.3K
- Earning Date
- DRTS 11-19-2024
- TIL 11-13-2024
- Dividend Yield
- DRTS N/A
- TIL N/A
- EPS Growth
- DRTS N/A
- TIL N/A
- EPS
- DRTS N/A
- TIL N/A
- Revenue
- DRTS N/A
- TIL N/A
- Revenue This Year
- DRTS N/A
- TIL N/A
- Revenue Next Year
- DRTS N/A
- TIL $2.65
- P/E Ratio
- DRTS N/A
- TIL N/A
- Revenue Growth
- DRTS N/A
- TIL N/A
- 52 Week Low
- DRTS $1.75
- TIL $7.10
- 52 Week High
- DRTS $3.40
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- DRTS 69.66
- TIL 39.40
- Support Level
- DRTS $3.03
- TIL $19.01
- Resistance Level
- DRTS $3.20
- TIL $21.90
- Average True Range (ATR)
- DRTS 0.09
- TIL 2.34
- MACD
- DRTS -0.02
- TIL -0.03
- Stochastic Oscillator
- DRTS 65.62
- TIL 16.83
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.